Navigation Links
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
Date:8/7/2009

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.

Dr. Fewell possesses more than 10 years management and scientific leadership experience in the biotechnology industry and has served at EGEN since 2003 as Director of Biology and Pharmacology. During his tenure at EGEN he has helped lead the development and testing of proprietary discovery and development initiatives contributing to a strong intellectual property position. He has been instrumental in building EGEN's research and development team and has helped foster important industry collaborations. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at Cincinnati's Children Hospital. During his active career in research and development, Dr. Fewell has authored numerous scientific publications and is a named inventor on several patents and patent applications in the area of non-viral gene and siRNA delivery.

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit '/>"/>

SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
2. AOBO Announces New Product Launch
3. Prix Galien USA Announces 2009 Final Candidates
4. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
5. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
6. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
7. Telik Announces Second Quarter 2009 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
9. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. Oncothyreon announces webcast of second quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Research and Markets ... and Proteomics Analytical Instruments Market 2014-2018" report to ... Genomics is the study of the gene ... the structure and functions of proteomes or sets of ... technology. Genomics involves the mapping of genes and DNA ...
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... ends the second quarter with more than $535 million in cash ... EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Aug. 7 Isis,Pharmaceuticals, Inc. ... ended June 30, 2008. The Company ended the quarter,in the strongest financial ...
... /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company focused ... of diseases and personalized health management, today reported,operational ... year to date,ended June 30, 2008., "The ... blood,test to assess a patient,s current risk of ...
... CHAMPAIGN, Ill. By combining stretchable optoelectronics and ... imaging device, with a layout based on the ... issue of the journal Nature, researchers ... have developed a high-performance, hemispherical "eye" camera using ...
Cached Biology Technology:Isis Reports Financial Results and Highlights for Second Quarter of 2008 2Isis Reports Financial Results and Highlights for Second Quarter of 2008 3Isis Reports Financial Results and Highlights for Second Quarter of 2008 4Isis Reports Financial Results and Highlights for Second Quarter of 2008 5Isis Reports Financial Results and Highlights for Second Quarter of 2008 6Isis Reports Financial Results and Highlights for Second Quarter of 2008 7Isis Reports Financial Results and Highlights for Second Quarter of 2008 8Isis Reports Financial Results and Highlights for Second Quarter of 2008 9Isis Reports Financial Results and Highlights for Second Quarter of 2008 10Isis Reports Financial Results and Highlights for Second Quarter of 2008 11Isis Reports Financial Results and Highlights for Second Quarter of 2008 12Isis Reports Financial Results and Highlights for Second Quarter of 2008 13Isis Reports Financial Results and Highlights for Second Quarter of 2008 14GeneNews Announces Second Quarter Results 2GeneNews Announces Second Quarter Results 3GeneNews Announces Second Quarter Results 4GeneNews Announces Second Quarter Results 5GeneNews Announces Second Quarter Results 6GeneNews Announces Second Quarter Results 7GeneNews Announces Second Quarter Results 8Stretchable silicon camera next step to artificial retina 2
(Date:7/25/2014)... that the age girls reach puberty is influenced by ,imprinted ... parent contributes the gene. This is the first evidence ... birth and details of this study were published today in ... period, known as menarche, is a marker for the timing ... onset of menses varies between girls, is an inherited trait, ...
(Date:7/25/2014)... use of a molecular testing panel developed at ... correct initial surgery for patients with thyroid nodules ... Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter., ... Center and other diagnostic testing agencies, improved the ... by 30 percent, according to the study published ...
(Date:7/25/2014)... Florida , July 25, 2014 ... more consumers are turning to digital technology for online ... (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ), ... (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... of scientists has, for the first time, completely characterized an ... ground-level ozone in urban areas. The team,s results indicate that ... during episodes of poor air quality (smoggy days) by as ... poses significant health hazards to people, animals and plants; is ...
... JOLLA, Calif., November 1, 2010 One of the many ... fat, which in turn supports a healthy heart. Fat tissue ... it,s also an active secretory organ that normally produces ... protects the hearts of healthy people has long been a ...
... " Environmental Pollution " details successful experiments at ... in the abiotic (non-biological) transformation and absorption of ... of these estrogen hormones by more than 80 ... implications since it could point to inexpensive treatment ...
Cached Biology News:Study improves accuracy of models for predicting ozone levels in urban areas 2Study improves accuracy of models for predicting ozone levels in urban areas 3Study improves accuracy of models for predicting ozone levels in urban areas 4Study finds fat hormone's long-sought link to heart protection 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... Western Protein Standards are specifically designed ... weight estimation directly on western blots. ... binding site, allowing direct visualization with ... detect your target protein on the ...
... Clone/PAD: 3F10B10. Immunogen: ... internal region of JAB1 (Jun ... Specificity: Specific for the ... (positive controls: 293T Jurkat cell ...
Biology Products: